Home / Expertise / Life Sciences & Healthcare

Life Sciences & Healthcare

United Kingdom

Discovery, innovation, market awareness and understanding are key to those life sciences and healthcare entities providing services and finance towards, and developing therapies and services for, the improvement of patient outcomes.

Due to the highly regulated nature of the industry, as an operator, investor, adviser, developer or licensee, you will be dealing with complex legal and regulatory requirements to launch, maintain and deliver your products and services to the market.

Our Life Sciences team is immersed in the sector and we appreciate our clients' technology; we are not just lawyers, we are immunologists, geneticists, chemists and engineers. With this background we are ideally placed to really understand your business, how it is changing and what you want from a trusted advisor. Highly relevant to this sector is our fully integrated European patent attorney practice. Spanning multiple disciplines, both legal and scientific, our lawyers and patent attorneys operate as one team with a common outlook and objective for our clients - providing pragmatic, innovative and effective advice, efficiently.

Our Healthcare team is truly immersed in the sector with over 25 years of advising and shaping the sector through in depth experience, knowledge and sector associations and collaborations. We have significant experience of working within the public and private sectors, giving us a complete perspective of the issues you face, allowing us to offer you commercial and well rounded advice.

With active memberships in major industry bodies such as the ABPI, ABHI, BIVDA, EUCOMED / MedTech Europe, Healthcare UK and the BPF, we help shape the legal and compliance frameworks impacting the life sciences and healthcare sectors.

As well as clients' significant, complex and strategic transactional, financing and structuring matters, we regularly advise on day-to-day business operations, covering areas such as public procurement, tax, competition, IP protection, exploitation and enforcement, product liability, supply chain, outsourcing and other commercial agreements and employment and pensions matters, as well as regulatory, disputes, risk and compliance advice. Truly a full service.

Read more Read less

"A one-stop-shop for us: its remarkable and successful mix of talent makes it stand out from the rest, and makes our lives much easier."

Chambers UK, 2015

Choose area


    Recent years have seen an increase in the numbers of biotech IPOs and more investment in the sector, however it can still be challenging accessing the finance necessary to fund R&D and to bring products to the market. As part of the biotech industry you will expect your lawyers to assist you in tackling these difficult financing and market challenges. Our team of sector specialists, including lawyers with technical backgrounds, understands the commercial drivers in this industry and can advise you on the full spectrum of legal matters.

    Read more

    Devices & Diagnostics

    In an increasingly competitive healthcare market, medical device and diagnostics companies need to ensure return on investment when developing innovative and reliable medical technologies and services. Devices and diagnostics are subject to complex regulatory and compliance frameworks and are often subject to competitive tendering so you will need lawyers who can reliably advise on pragmatic, compliant solutions.

    Read more


    With technology and digital innovation at the forefront of many advancements in the lifesciences industry and in healthcare delivery, organisations look  to consistently push boundaries to bring products and services to both the consumer and professional market. However, the regulation of ehealth solutions, devices and services is often outpaced by the novelty and innovation in the solutions themselves and at CMS, we understand the challenges this presents.

    Read more


    The healthcare sector in the UK and internationally continues to experience dynamic change underpinned by significant legal reforms. As an operator, investor, funder, developer or landlord in this sector, you are facing a highly regulated environment as well as significant public scrutiny.

    With increasing potential for the independent provision of health and social care along with an ageing population and technological advances, but with tightening public budgets, operating within the health and social care sectors presents both challenges and opportunities.

    Read more


    With ever increasing costs of gaining marketing authorisations for new drugs, fewer opportunities for blockbuster products and ongoing pressure on pricing, operating successfully in the pharmaceutical sector can be challenging. Our sector-focused team, many of whom have technical backgrounds, are able to help clients overcome these challenges and maximise the commercial opportunities.

    Read more
    equIP Life Sci­ences: from lab bench to busi­ness
    High­lights of our ex­per­i­ence in Life Sci­ences & Health­care in the UK
    Almir­all, S.A., on the trans­fer of its res­pir­at­ory fran­chise for an ini­tial con­sid­er­a­tion of USD 875m on com­ple­tion, and up to USD 1.22bn in de­vel­op­ment, launch and sales-re­lated mile­stone pay­ments.John­son & John­son on the UK as­pects of the sale of the Or­tho-Clin­ic­al Dia­gnostics busi­ness to The Carlyle Group.PGT Health­care LLP, a joint ven­ture cre­ated by Proc­tor & Gamble, on an in­nov­at­ive col­lab­or­a­tion agree­ment with Swisse Well­ness Group Pty Lim­ited, Aus­tralia’s lead­ing ‘well­ness’ brand. The col­lab­or­a­tion relates to vit­am­in, min­er­al and food sup­ple­ment products, which will be mar­keted across a num­ber of ter­rit­or­ies and was one of the biggest ever li­cens­ing deals for an Aus­trali­an com­pany.Fran­cis Crick In­sti­tute on the trans­fer of re­search activ­it­ies and as­so­ci­ated as­sets from the Med­ic­al Re­search Coun­cil and Can­cer Re­search UK.Per­rigo Com­pany on the ac­quis­i­tion of Rose­mont Phar­ma­ceut­ic­als Ltd for GBP 180m.Uni­versity of Glas­gow on all leg­al mat­ters rel­ev­ant to the es­tab­lish­ment of the Strat­i­fied Medi­cine Scot­land In­nov­a­tion Centre (SMS-IC), an ini­ti­at­ive fun­ded by the Scot­tish Fund­ing Coun­cil.Great Or­mond Street Hos­pit­al in con­nec­tion with its high-pro­file GBP 320m re­devel­op­ment.Take­da Phar­ma­ceut­ic­al Com­pany Lim­ited on the EUR 9.6bn (debt-free cash free) ac­quis­i­tion of Swiss drug com­pany, Nycomed A/S. This was one of the most sig­ni­fic­ant deals to oc­cur in the lifes­ci­ences sec­tor, with this ac­quis­i­tion in­creas­ing Take­da’s foot­print and strength in the European mar­ket and emer­ging mar­kets.Ab­bVie on lit­ig­a­tion by Chemistree Home­care re­gard­ing re­fus­al to sup­ply claims for spe­cif­ic spe­cial­ist medi­cines.Wellcome Trust on the first euro-de­nom­in­ated bond is­sue, which raised EUR 400m for its im­port­ant med­ic­al re­search work as one of the world’s largest char­it­able found­a­tions.Please down­load the print ver­sion be­low.
    Law-Now: Lifes­ci­ences
    Vis­it Law-Now for leg­al know-how and com­ment­ary


    Show only
    15 April 2020
    CMS wins four gongs at the 2019 CEE Leg­al Mat­ters Deal of the Year Awards
    Deal of the Year Awards. CMS was in­volved in 12 of the nom­in­ated deals and the firm has won for its work on lead­ing trans­ac­tions in Bul­garia, Czech Re­pub­lic, Montenegro and North Mace­do­nia – show­cas­ing the firm’s strength across the CEE re­gion.
    20 April 2020
    CMS Ex­pert Guide to Ad­vert­ising of Medi­cines and Med­ic­al Devices
    This Ex­pert Guide provides high level in­form­a­tion on life sci­ences and health­care ad­vert­ising in 27 jur­is­dic­tions and of­fers a quick and simple un­der­stand­ing of the ap­plic­able laws. The Ex­pert Guide cov­ers, amongst oth­ers, dif­fer­ent types of ad­vert­ising, reg­u­lat­ory as­pects as well as leg­al con­sequences of non-com­pli­ance.
    29 May 2020
    The On­line Harms White Pa­per: can pro­gress be made dur­ing the COV­ID-19...
    In March 2020, the In­de­pend­ent In­quiry in­to Child Sexu­al Ab­use (“the In­quiry”) pub­lished The In­ter­net In­vest­ig­a­tion Re­port (“the Re­port”) which con­cluded that reg­u­la­tion of the in­ter­net in­dustry...
    9 April 2020
    Rene­go­ti­at­ing or can­cel­ling com­mer­cial ar­range­ments in light of COV­ID-19
    Rene­go­ti­at­ing or can­cel­ling com­mer­cial ar­range­ments in light of COV­ID-19. Read this Coronavir­us pa­per from CMS now.
    20 April 2020
    CMS Ex­pert Guide to a Leg­al Roadmap to Can­nabis
    26 May 2020
    European Com­mis­sion must ad­dress in­tel­lec­tu­al prop­erty and AI
    The Com­mit­tee on Leg­al Af­fairs (JURI) of the European Par­lia­ment has pub­lished three draft re­ports re­lat­ing to ar­ti­fi­cial in­tel­li­gence (AI). This note is about the draft re­port on in­tel­lec­tu­al prop­erty...
    13 January 2020
    High­lights of our ex­per­i­ence in Health­care
    22 May 2020
    For­eign in­vest­ments in Ger­man life sci­ence com­pan­ies be­come sub­ject to...
    In re­sponse to the COV­ID-19 pan­dem­ic, Ger­many has widened the scope of its in­vest­ment con­trol to in­clude nu­mer­ous life sci­ence com­pan­ies. The amend­ments to the For­eign Trade and Pay­ments Or­din­ance ("AWV")...
    November 2019
    equIP Life Sci­ences: from lab bench to busi­ness
    Sup­port­ing the growth of com­pan­ies across bi­otech, phar­ma­ceut­ic­als, devices & dia­gnostics, di­git­al health and health­care
    19 May 2020
    Changes to CCFF, the UK Gov­ern­ment’s large busi­ness sup­port scheme
    Changes have been an­nounced today to the Cov­id Cor­por­ate Fin­an­cing Fa­cil­ity (CCFF), the UK Gov­ern­ment’s li­quid­ity sup­port scheme for lar­ger busi­nesses in­volving the pur­chase of com­mer­cial pa­per, a type...
    30 October 2019
    CMS ad­vises Ad­vent In­ter­na­tion­al and Zentiva on ac­quis­i­tion of Al­vo­gen’s...
    CMS ad­vises Ad­vent In­ter­na­tion­al and Zentiva on ac­quis­i­tion of Al­vo­gen’s CEE busi­ness. Find out more.
    07 May 2020
    COV­ID-19: Gov­ern­ment Guid­ance up­date on pla­cing new PPE on the mar­ket
    Cor­rect as of 9am, 07th May. This art­icle is not be­ing main­tained. The Gov­ern­ment has re­cently up­dated guid­ance on pla­cing new Per­son­al Pro­tect­ive Equip­ment (PPE) on the mar­ket. In light of the need for...